Marinus Pharmaceuticals insider Gail M. Farfel Sells 30,000 Shares (MRNS)

Print 24 April 2015
Seth Barnet / WKRB News

Marinus Pharmaceuticals (NASDAQ:MRNS) insider Gail M. Farfel sold 30,000 shares of Marinus Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $9.48, for a total value of $284,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Oppenheimer reiterated an “outperform” rating and set a $12.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, March 16th.

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) traded up 1.22% on Friday, hitting $9.15. 3,750 shares of the company’s stock traded hands. Marinus Pharmaceuticals has a 52-week low of $4.00 and a 52-week high of $16.60. The stock has a 50-day moving average of $9. and a 200-day moving average of $9.. The company’s market cap is $129.92 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings data on Thursday, March 12th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $1.01. Analysts expect that Marinus Pharmaceuticals will post $-1.87 EPS for the current fiscal year.

Marinus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, an endogenous neurosteroid produced in the central nervous system that modulates the brain neurotransmitter gamma-aminobutyric acid (NASDAQ:MRNS).



All Portfolio


  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news